Use your antibodies-online credentials, if available.
抗Mouse (Murine) 抗体:
抗Rat (Rattus) 抗体:
Human Polyclonal Lp-PLA2 Primary Antibody for IF (p), IHC (p) - ABIN686722
Rosing, Fobker, Kannenberg, Gunia, DellAquila, Kwiecien, Stypmann, Nofer: Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. in Atherosclerosis 2013
Show all 2 Pubmed References
Human Monoclonal Lp-PLA2 Primary Antibody for ELISA - ABIN563501
Klee, Finlay, McDonald, Attewell, Hebrink, Dyer, Love, Vasmatzis, Li, Beechem, Klee: Bioinformatics methods for prioritizing serum biomarker candidates. in Clinical chemistry 2007
Human Polyclonal Lp-PLA2 Primary Antibody for ELISA, WB - ABIN4238414
Moldoveanu, Serban, Marta, Serban, Huica: Lipoprotein-associated phospholipase A2 activity in patients with preserved left ventricular ejection fraction. in Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2011
Human Polyclonal Lp-PLA2 Primary Antibody for FACS, IHC (p) - ABIN653776
Bouchareb, Mahmut, Nsaibia, Boulanger, Dahou, Lépine, Laflamme, Hadji, Couture, Trahan, Pagé, Bossé, Pibarot, Scipione, Romagnuolo, Koschinsky, Arseneault, Marette, Mathieu: Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic Valve. in Circulation 2015
While higher Lp-PLA2 activity was associated with an increased risk for incident peripheral arterial disease, it is likely a risk marker largely represented by traditional risk factors.
Impact of a non-synonymous Q281R polymorphism on structure of human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2 ).
Results provide strong evidence for the association of rs10846744, which resides within an enhancer region, with Lp-PLA2 activity and evidence from a number of large genetic studies for association with cardiovascular disease events.
Lp-PLA2 activity was higher in definite FH than in non-definite FH patients independently of LDL-C levels and statin treatment.
in preeclampsia, higher vascular inflammation which was shown by Lp-PLA2 mass, Lp-PLA2 index, and PTX3 levels were significantly associated with rs9381475, rs1051931 carriers. Further, Lp-PLA2 activity and PTX3, Lp-PLA mass has independently associated with early preeclampsia.
adipose tissue and adipocytes are active sources of Lp-PLA2, with differential regulation by fat depot and metabolic state
Lp-PLA2 increases are associated with increased risk of death and the development of incident diabetic retinopathy, as well as transitions to more severe grades of diabetic retinopathy
The decrease of Lp-PLA2 activity in adolescents with type 2 diabetes suggests that elevated blood glucose concentrations do not have a dominant elevating effect, perhaps even a decreasing influence on Lp- PLA2 activity.
Polymorphisms in rs1805017 and rs1805018, additional interaction between rs1805017 and smoking, and haplotype containing the rs1805017-H and rs1805018-T alleles were associated with increased CHD risk.
CD163 positive macrophages have roles in lipoprotein-associated phospholipase A2 activity in atherosclerotic plaque
evidence that Lp-PLA2 could predict all-cause mortality and rehospitalization risk among patients with ACS undergoing PCI.
the relationship between two variants of apoC1 and the risk of polycystic ovary syndrome, evaluated the genotypic effects on clinical, hormonal and metabolic indexes and plasma platelet-activating factor acetylhydrolase (PAF-AH) activity, was investigated.
Met117 oxidation caused enhanced flexibility and decreased compactness in oxidized state. PAF binding interaction with oxidized protein was mediated only through hydrophobic interactions.
Persistently elevated serum concentrations of Lp-PLA2 were associated with an unfavorable outcome in patients with sepsis.
Resveratrol downregulates Lp-PLA2 expression by inhibiting oxidative stress via SIRT1 pathway in the THP-1-derived macrophages.
Elevated Lp-PLA2 mass was associated with all cause-death independently of other risk factors within one year after acute ischemic stroke.
PLA2G7 and PON1 are overexpressed in prostatic neoplasm patients and can be detected early in blood.
A PLA2G7 gene polymorphism determines the plasma levels of lipoprotein-associated phospholipase A2 activity and mass and manifests as a risk factor for atherosclerosis.
Conclusion RBP4 may be used as a predictive factor of diabetic nephropathy patients complicated with silent cerebral infarction (SCI) and is positively correlated with cognitive dysfunction. RBP4/Lp-PLA2/Netrin-1 pathway activation may be one of the occurrence mechanisms in diabetic nephropathy complicated with SCI.
Greater Lp-PLA2 activity or mass was associated with an increased risk of CHD and IS
The results demonstrated that Lp-PLA2 is associated with triglycerides which may be helpful for understanding the relationship of this protein with cardiovascular disease.
Effect of splenectomy and autologous spleen transplantation on the serum PAF-AH activity and acute-phase response in a porcine model are reported.
observations support a proatherogenic role for Lp-PLA2
Variable gene expression (eg, matrix metalloproteinase-9, CCL2 and Lp-PLA(2) mRNAs), both in regard to the arterial bed and duration of disease, was associated with variable plaque development and progression.
The significant correlation between PLA2G7 RNA expression in plaque macrophages and plasma PAFAH activity suggests that the latter is a consequence, rather than a cause of macrophage accumulation.
Resveratrol downregulates Lp-PLA2 expression by inhibiting oxidative stress via SIRT1 pathway in a mouse model of chronic inflammation.
Lp-PLA2 augments the inflammatory response after MI and antagonizes healing by disrupting the balance between inflammation and repair.
Plg from mouse plasma contains oxPtdPC adducts that are not affected by the action of Lp-PLA(2), suggesting that linkage to Plg protects oxPtdPCs from metabolism during their transport in the plasma.
SAA up-regulates Lp-PLA2 production significantly via a FPRL1/MAPKs./PPAR-gamma signaling pathway.
Deletion of Pla2g7 decreases small intestinal polyp and colon tumor incidence in ApcMin/+ mice.
Macrophage VLDL receptor promotes PAFAH secretion in mother's milk and suppresses systemic inflammation in nursing neonates.
Pla2g7 and Tnfrsf21 have been identified as genetic susceptibility to influenza genes in mice.
Pla2g7 plays a crucial physiological role in smooth muscle cell differentiation from stem cells, and interactions between Nrf3 and Pla2g7 are essential.
The effects of a specific lp-PLA2 inhibitor on atherosclerosis in ApoE-deficient mice and its associated mechanisms, are reported.
Studies designed to evaluate the ability of precursor forms of PAF-AH to mature to fully active proteins indicated that the N-terminal end of human and mouse PAF-AH played important and opposite roles in this process.
PAF acetylhydrolase activity in the uterus in early pregnancy was not produced locally but probably resulted from the influx of the plasma form of the enzyme
deletion of both subunits induces a marked loss of germ cells at an early spermatogenic stage.
PAF acetylhydrolases play key roles in the hydrolysis of F2-isoprostanes esterified on phospholipids in vivo
over-expression of the PAF-AH (I) catalytic subunits induces centrosomal amplification and microtubule disorganization by disturbing intracellular localization of LIS1
inactivation of PAF, produced by TEC, by the overexpression of plasma PAF-AH affects survival, migration, and the angiogenic response of TEC both in vitro and in vivo
mouse and human PAF-AHs associate with human HDL particles of different density
The protein encoded by this gene is a secreted enzyme that catalyzes the degradation of platelet-activating factor to biologically inactive products. Defects in this gene are a cause of platelet-activating factor acetylhydrolase deficiency. Two transcript variants encoding the same protein have been found for this gene.
, 2-acetyl-1-alkylglycerophosphocholine esterase
, LDL-associated phospholipase A2
, PAF 2-acylhydrolase
, PAF acetylhydrolase
, group-VIIA phospholipase A2
, lipoprotein-associated phospholipase A2
, platelet-activating factor acetylhydrolase
, group VII phospholipase A2
, plasma PAF acetylhydrolase